Updated:
Mediqventures
Mediqventures invests in companies with late-stage preclinical or early-stage clinical therapeutic assets, focusing on metabolic disease, oncology, and...
Mediqventures
Mediqventures invests in companies with late-stage preclinical or early-stage clinical therapeutic assets, focusing on metabolic disease, oncology, and infectious disease. The firm has made one investment. Its latest investment was in Causeway Therapeutics as part of their Series A on February 22, 2023.
General information
Firm type
Venture Capital
Year founded
2011
Location
Region
Europe
Country
United Kingdom
City
Douglas
Corporate office
Douglas, Isle of Man, United Kingdom
Sector focus
Frequently asked questions
Why is Mediqventures domiciled in the Isle of Man?
The Isle of Man is a crown dependency outside the UK with its own regulatory, tax, and company-law framework. Funds domiciled there can access EU and UK markets while operating under a lighter-touch regulatory regime than onshore vehicles, making the jurisdiction attractive for specialist funds raising institutional capital across borders.
Does Mediqventures disclose its assets under management or fund size?
No. Neither AUM, deployment totals, individual fund sizes, nor fund-vintage years appear in any public primary source. The firm operates without the kind of public transparency typical of larger buyout or growth houses, meaning LP commitments are not observable from outside the firm.
Who runs investment decisions at Mediqventures?
No named principals, investment committee members, or deal leads are documented in public records for Mediqventures. The firm does not publish team profiles on its website, and no principal-level names surfaced in corporate registries or media coverage as of mid-2026.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: